[Alpha Biz= Kim Jisun] Yuhan Corporation announced on May 6 that it has signed an active pharmaceutical ingredient (API) supply agreement with BridgeBio Pharma for a cardiomyopathy treatment.

The contract is valued at approximately $38.08 million (KRW 56 billion), equivalent to about 2.56% of Yuhan’s annual revenue of KRW 2.1866 trillion recorded last year. The agreement will run from May 5, 2026, through March 1, 2028.

BridgeBio Pharma, a Nasdaq-listed biotechnology company based in the United States, focuses on the development of therapies for genetic and cardiovascular diseases.

 

 

[ⓒ 알파경제. 무단전재-재배포 금지]